Global cancer anorexia-cachexia syndrome market to reach $6.37B by 2030 at 10.4% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Cancer Anorexia-Cachexia Syndrome (CACS) Market Projected To Reach By 2030?
The cancer anorexia-cachexia syndrome (cacs) market has experienced rapid expansion in recent years. It is projected to grow from $3.88 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This growth observed in previous periods can be linked to the increasing occurrence of advanced cancer cases, a heightened awareness of cachexia’s effect on treatment results, the initial clinical deployment of appetite stimulants, the development of hospital-based supportive care initiatives, and the broadening of oncology nutrition research.
The market for cancer anorexia-cachexia syndrome (cacs) is projected to experience substantial expansion over the upcoming years, anticipated to reach $6.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this projected growth include rising investments in developing cachexia drugs, an increasing emphasis on personalized oncology supportive care, heightened clinical trial activity for new therapeutic agents, the broadening of home-based cancer care services, and the greater incorporation of cachexia management within oncology protocols. Key trends anticipated during this period involve the intensified development of targeted therapies for cachexia, a greater concentration on anti-inflammatory treatment methods, the increasing implementation of combination therapeutic strategies, an expansion of nutritional and metabolic support options, and a stronger focus on early intervention for cachexia.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth?
The increasing incidence of cancer is anticipated to drive the expansion of the cancer anorexia-cachexia syndrome market in the future. Cancer is a broad term for a range of diseases marked by the uncontrolled multiplication and spread of abnormal cells within the body. Global cancer rates are on the rise due to various factors, including an aging population, shifts in lifestyle, environmental exposures, advancements in detection methods, heightened public awareness, along with genetic predispositions and infections linked to specific cancers. Cancer anorexia-cachexia syndrome (CACS) addresses this growing cancer prevalence by concentrating on managing the severe weight loss and malnutrition frequently observed in cancer patients, thereby improving their overall quality of life and treatment outcomes. For instance, in August 2024, a report from the UK-based charitable organization Macmillan Cancer Support revealed that over 3 million people in the UK are living with cancer, a number projected to grow to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is a key driver for the growth of the cancer anorexia-cachexia syndrome market.
How Is Segmentation Applied In The Cancer Anorexia-Cachexia Syndrome (CACS) Market Segment Analysis?
The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
Which Trends Are Contributing To Changes In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Leading companies in the cancer anorexia-cachexia syndrome market are concentrating on developing innovative solutions, such as monoclonal antibody therapies, to improve treatment effectiveness, enhance patient outcomes, and address existing clinical needs. Monoclonal antibody treatments involve the use of laboratory-produced antibodies engineered to target specific antigens on cancer cells, thereby helping the immune system more effectively identify and attack them. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced positive results from a Phase II clinical trial for ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15). The promising data from this study provides hope for a novel treatment approach for patients suffering from this debilitating condition, for which few effective therapies currently exist. The Phase 2 trial results indicate significant progress in addressing the underlying inflammatory processes that contribute to muscle loss and weight decline in cancer patients. This treatment approach aims to not only improve physical function but also to enhance the overall quality of life for cancer patients, marking a crucial step in oncology care.
Who Are The Companies Participating In The Cancer Anorexia-Cachexia Syndrome (CACS) Market Environment?
Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.
Get The Full Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:
Which Region Is The Leading Market For The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cancer Anorexia-Cachexia Syndrome (CACS) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company
Progressive Ataxia And Weakness Disorders Market Report 2026
Anorectal Disorders Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report
Oncology Nutrition Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
